Category: Volcano Corp.
Medical device executives surveyed by the Medical Device Manufacturers Assn. say they'll step up hiring if the medical device tax is repealed.
Repealing the job-killing medical device tax will serve as job creator, a survey of medical device executives revealed today.
Here's a look at some of the top Wall Street stories for medical device companies this week: Year in review: 2014 was the year of the medtech IPO; Symmetry Medical closes surgical spinout, OEM sale; Inogen affirms 2014 outlook, predicts 2015 growth of up to 25%
, Johnson & Johnson
, Nevro Corp.
, Ocular Therapeutix Inc.
, Symmetry Medical Inc.
, Symmetry Surgical
, Tecomet Inc.
Royal Philips agrees to pay $1.2 billion to acquire Volcano Corp. and its cardiovascular imaging technology.
The number of initial public offerings for medical device companies jumped fourfold in 2014, according to a MassDevice.com analysis.
Click to enlarge
It was, as predicted, the year of the IPO for medical device companies, with 25 filing initial public offerings during 2014, according to a MassDevice.com analysis.
Manufacturers of inferior vena cava filters and 2 medical societies team up for a large-scale study of the pulmonary embolism preventers, 4 years after an FDA warning about the devices.
The Society of Interventional Radiology, the Society for Vascular Surgery and 7 medical device companies are teaming up for the 1st large-scale study of inferior vena cava filters, 4 years after an FDA warning that the devices might dislodge or fracture.
Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific could take CRM lead; Orthofix CFO bails after 6 months amid deepening financial fix; Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien; Echo Therapeutics is on the ropes; Activist investor erupts at Volcano
, Boston Scientific
, Echo Therapeutics Inc.
, Engaged Capital
, Food & Drug Administration (FDA)
, Leerink Swann
, Orthofix International
, pSivida Corp.
, St. Jude Medical
, Alimera Sciences
Activist investor fund Engaged Capital ups the pressure on Volcano Corp., scolding it for its $116 million AtheroMed acquisition and missing chances to sell itself at a premium.